Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1Lung Diseases 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × zipalertinib × Thoracic × Clear all
NCT07128199 2026-05-05

REZILIENT4

Taiho Oncology, Inc.

Phase 3 Active not recruiting
360 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting
285 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting
284 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡